Gilead Sciences | GILD

Stock Price
65.07
Daily Change
-1.83 -2.73%
Monthly
-10.14%
Yearly
-22.30%
Q2 Forecast
71.85
Peers Price Chg Day Year Date
ABBV AbbVie 167.20 -0.81 -0.48% 3.34% Apr/25
AGIO Agios Pharmaceuticals 31.67 0 0% 43.30% Apr/25
ALKS ALKERMES 24.44 0.37 1.52% -13.90% Apr/25
ALNY Alnylam Pharmaceuticals 143.70 -0.09 -0.06% -27.25% Apr/25
AMGN Amgen 269.42 -3.72 -1.36% 12.82% Apr/25
BIIB Biogen 202.49 0.36 0.18% -29.70% Apr/25
BMRN BioMarin Pharmaceutical 82.17 -9.07 -9.94% -11.65% Apr/25
BMY Bristol-Myers Squibb 44.70 -4.16 -8.51% -34.28% Apr/25
GILD Gilead Sciences 65.07 -1.83 -2.73% -22.30% Apr/25
GSK GlaxoSmithKline 1,639.00 -1.50 -0.09% 14.06% Apr/26
GSK Glaxosmithkline 40.91 0.05 0.12% 13.86% Apr/25
INCY Incyte 51.16 -0.62 -1.20% -30.43% Apr/25
JNJ J&J 146.84 -1.73 -1.16% -9.70% Apr/25
LLY Eli Lilly 729.01 -8.11 -1.11% 93.75% Apr/25
MRK Merck 130.49 3.59 2.83% 15.04% Apr/25
MRNA Moderna 106.22 -2.79 -2.56% -18.75% Apr/25
NBIX Neurocrine Biosciences 137.73 -1.24 -0.89% 34.08% Apr/25
NOVN Novartis 89.48 -0.52 -0.58% -2.05% Apr/26
PFE Pfizer 25.26 -0.97 -3.69% -34.61% Apr/25
PTCT PTC Therapeutics 25.49 0.28 1.11% -51.21% Apr/25
REGN Regeneron Pharmaceuticals 906.54 -16.99 -1.87% 16.52% Apr/25
SAN Sanofi 90.12 -1.51 -1.64% -11.50% Apr/26
SRPT Sarepta Therapeutics 127.41 3.16 2.54% 4.20% Apr/25
UTHR United Therapeutics 235.98 -1.02 -0.43% 4.48% Apr/25
VRTX Vertex Pharmaceuticals 397.24 -3.35 -0.84% 22.87% Apr/25

Indexes Price Day Year Date
SPX US500 5083 -23.21 -0.46% 22.90% Apr/26
CCMP USND 15612 -100.99 -0.64% 31.70% Apr/25
NDX US100 17430 -96.30 -0.55% 36.11% Apr/25
US100 US100 17597 -96.30 -0.55% 33.72% Apr/26

Gilead Sciences traded at $65.07 this Thursday April 25th, decreasing $1.83 or 2.73 percent since the previous trading session. Looking back, over the last four weeks, Gilead Sciences lost 10.14 percent. Over the last 12 months, its price fell by 22.30 percent. Looking ahead, we forecast Gilead Sciences to be priced at 71.85 by the end of this quarter and at 67.81 in one year, according to Trading Economics global macro models projections and analysts expectations.

Gilead Sciences, Inc. is a biopharmaceutical company that is focused on advancing medicines to prevent and treat diseases, including human immunodeficiency virus (HIV), viral hepatitis and cancer. The Company's portfolio of products and pipeline of investigational drugs includes treatments for HIV/acquired immune deficiency syndrome (AIDS), COVID-19, liver diseases, hematology/oncology/cell therapy and other. Its products for HIV/AIDS patients include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Truvada and Atripla. It offers Veklury to patients with COVID-19. The Company's products for patients with liver diseases include Vemlidy, Epclusa, Harvoni, Viread and Vosevi. Its products under hematology/oncology/cell therapy include Yescarta, Tecartus, Trodelvy and Zydelig. Other products include Letairis, Ranexa and AmBisome. Its products for various inflammation/respiratory diseases include Cayston and Tamiflu. The Company operates in more than 335 countries worldwide.